
High levels of arsenic and cadmium found in rice sold in stores across U.S., report finds
A new report is bringing attention to toxic heavy metals and elements such as arsenic, cadmium, lead and mercury that could be in your rice.
The report, which comes from Healthy Babies, Bright Futures, an organization focused on babies' exposure to toxic chemicals, found arsenic in 100% of rice samples purchased from stores across the U.S.
One in four rice samples also exceeded the federal limit of 100 parts per billion (ppb) of inorganic arsenic set by the U.S. Food and Drug Administration for infant rice cereal in 2021, according to the report.
"No such limit exists for rice itself - the bags and boxes of rice served at family meals - despite it being widely consumed by infants and toddlers," the authors note.
Overall, the levels of total heavy metals, including cadmium, lead and mercury, ranged, on average, from 63 ppb to 188 pbb among the rice samples — though some samples exceeded 240 ppb, for example.
The report tested 105 different brands, including Trader Joe's, Ben's and Goya, from 20 metro areas across the country, from New York City to Los Angeles and Miami. Of the four toxic heavy metals found, arsenic was found at the highest levels and cadmium was second. Lead and mercury were found at the lowest levels.
In an emailed statement to CBS News, the USA Rice Federation said Thursday, "We know that arsenic in food is alarming for many consumers and that you may have questions. And while we do not agree that there is a public health safety issue as a result of trace amounts of arsenic in rice, we will continue to work with the U.S. Food and Drug Administration to ensure the U.S. rice supply meets any threshold established."
Very low levels of inorganic and organic arsenic are found in many food products, according to the National Institutes of Health.
Inorganic arsenic is more toxic to humans than the naturally occurring form of the mineral arsenic, and the health effects from exposure are more severe, according to the FDA. The Environmental Protection Agency has labeled inorganic arsenic a carcinogen, or a substance that causes cancer.
For those looking to reduce exposure, Healthy Babies, Bright Futures suggested a few options:
Cook rice like pasta: "Research shows that cooking rice in 6 to 10 cups of water per 1 cup of rice and draining the excess water before eating can remove a significant amount of arsenic," the report read.
Use rice alternatives: The organization's testing found alternatives such as quinoa, barley and couscous contain lower levels of total heavy metals.
Choose your rice wisely: The organization also found some types of rice had higher levels of heavy metals and elements than others. They suggest opting for Calrose, sushi, and white rice grown in California, along with jasmine rice from Thailand or Basmati rice from India, while avoiding those found to have higher levels, such as brown rice, white rice grown in the Southeast U.S. and arborio rice (risotto) from Italy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
22 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
3 hours ago
- Yahoo
An OpenAI exec says she was diagnosed with breast cancer and that ChatGPT has helped her navigate it
Kate Rouch, OpenAI's chief marketing officer, said she was diagnosed with breast cancer. Rouch said she is expected to make a full recovery and urged other women to prioritize their health. She said she leaned on OpenAI's ChatGPT to navigate her treatment. Kate Rouch, the chief marketing officer at OpenAI, shared on Friday that she was diagnosed with invasive breast cancer weeks after assuming the role, which she called her "dream job," in December. In a thread posted on X, Rouch said she was sharing her story to help other women, adding, "We can't control what happens to us--but we can choose how we face it. My biggest lesson: no one fights alone." Prior to joining OpenAI as the company's first CMO, Rouch was CMO at Coinbase and, before that, spent over a decade at Meta, including as vice president, global head of brand and product marketing. Rouch said she started treatment right around the Super Bowl in February, when OpenAI aired its first-ever ad, and that she has since gone through 13 rounds of chemotherapy while leading OpenAI's marketing team. She wrote that she is expected to make a full recovery. "It has been the hardest season of life — for me, for my husband, and for our two young children," Rouch said, adding she has been supported by OpenAI "at every step." "Silicon Valley can be brutal and transactional. And yet — I've never felt more held," she said, adding that "people showed up in incredible and unexpected ways." Rouch also said OpenAI's ChatGPT has helped her navigate her diagnosis and treatment, including by explaining cancer in a way that is age-appropriate for her kids, helping her manage the side effects of chemo, and creating custom meditations. "Experiencing our work as a patient has made OpenAI's mission feel more personal and important," she said. Rouch said she was sharing her story to encourage other women to "prioritize their health over the demands of families and jobs." "A routine exam saved my life. It could save yours, too," she said. Business Insider reached out to OpenAI for comment. Kevin Weil, the chief product officer at OpenAI, expressed support for Rouch in a reply to her thread. "We love you @kate_rouch!" he wrote. "Proud of you for telling your story and for being so full of fight." Read the original article on Business Insider
Yahoo
3 hours ago
- Yahoo
Hillsborough County installing AEDs at 25 parks and sports complexes
The Brief Hillsborough County is installing AEDs at 23 parks and sports complexes. The AEDs were funded by the American Heart Association. The AEDs will be available for anyone to use in the event of a cardiac emergency. TAMPA, Fla. - Hillsborough County is equipping about two dozen of its parks with emergency gear in the event of a cardiac emergency. The county will install 25 AEDs, automated external defibrillators, at 23 parks and sports complexes across the county. Follow FOX 13 on YouTube What we know The American Heart Assocation funded the purchase of 25 AEDs for the Hillsborough County parks and sports complexes. The first AED has been installed at the Skyway Sports Complex. It will be one of two parks that will have two AEDs onsite, because of its size. "We're going to focus on putting these AEDs in sports complexes like this one that are very, very busy with thousands of users," Mikah Collins of Hillsborough County Parks and Recreation said. "But, we're also going to put them in our parks that are way out in the middle of nowhere, and that's going to be even more important, because it takes so long for an ambulance or first responders to get there." READ: Tampa Police get 300 new lifesaving choking devices from New York-based company The AEDs will be available for public use in the event of a cardiac emergency. The American Heart Association of Tampa Bay said if someone goes into cardiac arrest, when you call 911, dispatchers will give you a code to unlock the box containing the AED. "As soon as you open the machine, it's going to start talking, and it's going to tell you exactly what to do," Courtney Burt, the vice president of community impact with the American Heart Association of Tampa Bay, said. Burt said someone else should be performing CPR while the person is accessing the AED, and you're waiting for EMS to arrive. MORE: Tampa's SoHo braces for stormwater project amid business concerns By the numbers The American Heart Association said the first two minutes of someone going into cardiac arrest are the most important in terms of response. "CPR actually raises a person's chance of survival about two to three times," Burt said. "When we introduce an AED within that two-minute window, it can actually increase their survivability up to almost 70%." Burt said about 1,000 people a day in the U.S. have an out-of-hospital cardiac arrest. She said a person's chance of surviving an out-of-hospital cardiac arrest is less than 10%. "With an AED, it really probably triples your likelihood of surviving a major heart attack," Dr. Doug Ross, the chief medical officer of the AdventHealth West Florida division, said. Dig deeper Ross said an AED can be the difference between life and death. He said the machines are user-friendly and designed to be used by people who are not trained with them. READ: Week-long active threat training held with Hillsborough County deputies "Talks you through it. These are very automatic, you know," Ross said. "You turn it on, it talks you through how to put the pads on, what to do. It'll analyze the heart rhythm. And then, if you need to be shocked, then it tells you to push the button to shock." There's a growing movement to make AEDs more accessible. Governor Ron DeSantis signed House Bill 1607, which will require school districts to provide basic first aid training to certain students. It will also require every public school and charter school to have at least one AED on campus by July 1, 2027. "Not only will it help get funding and resources for schools to have the devices, but also the education related to CPR and policies that we call 'Cardiac Emergency Response Plans,'" Burt said. The new Florida law will go into effect on July 1. What's next Hillsborough County officials are installing the AEDs at the county parks and sports complexes and connecting them with 911 now. They hope the AEDs will be ready for use by August. WATCH FOX 13 NEWS: STAY CONNECTED WITH FOX 13 TAMPA: Download the FOX Local app for your smart TV Download FOX Local mobile app:Apple |Android Download the FOX 13 News app for breaking news alerts, latest headlines Download the SkyTower Radar app Sign up for FOX 13's daily newsletter